Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron

Background and Objectives Mirabegron, a selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), is eliminated by renal and metabolic routes. The potential influence of renal or hepatic impairment on the pharmacokinetics of mirabegron was evaluated.